|Bid||6.03 x 900|
|Ask||6.04 x 1000|
|Day's Range||5.81 - 6.13|
|52 Week Range||1.93 - 8.56|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The drop came after Sarepta Therapeutics (NASDAQ: SRPT) reported disappointing clinical results for experimental gene therapy SRP-9001 in treating rare genetic disease Duchenne muscular dystrophy (DMD). Sarepta's problem was that SRP-9001 didn't meet the primary functional endpoint of its clinical study. Just because SRP-9001 failed in a clinical study doesn't necessarily mean that SGT-001 will.
Ultragenyx (RARE), which has a strong pipeline, receives a few approvals for its products in 2020.
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today